Wyeth Effexor Label Revised With Suicide-Related Adverse Events Precaution
Executive Summary
Revised labeling for Wyeth's Effexor contains a precaution on reports of hostility and suicide-related adverse events in pediatric clinical trials with the serotonin and norepinephrine reuptake inhibitor
You may also be interested in...
FDA Requests Antidepressant Labeling Add Suicidality Warning
FDA is requesting that labeling for 10 antidepressants include a warning recommending close monitoring of adult and pediatric patients for suicidal behavior
FDA Requests Antidepressant Labeling Add Suicidality Warning
FDA is requesting that labeling for 10 antidepressants include a warning recommending close monitoring of adult and pediatric patients for suicidal behavior
Antidepressant Labeling Should Reflect Negative Pediatric Studies
Antidepressant labeling should be revised to reflect negative efficacy data for pediatric patients, a joint FDA advisory committee suggested Feb. 2